Zobrazeno 1 - 10 of 16 pro vyhledávání: '"Moerke NJ"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Akademický článek
Discovery of DNL343: A Potent, Selective, and Brain-Penetrant eIF2B Activator Designed for the Treatment of Neurodegenerative Diseases.
Autor: Craig RA 2nd; Denali Therapeutics Inc., South San Francisco, California 94080, United States., De Vicente J; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Estrada AA; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Feng JA; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Lexa KW; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Canet MJ; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Dowdle WE; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Erickson RI; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Flores BN; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Haddick PCG; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Kane LA; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Lewcock JW; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Moerke NJ; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Poda SB; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Sweeney Z; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Takahashi RH; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Tong V; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Wang J; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Yulyaningsih E; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Solanoy H; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Scearce-Levie K; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Sanchez PE; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Tang L; Department of Chemistry, WuXi AppTec Co., Ltd., Tianjin 300457, China., Xu M; Department of Chemistry, WuXi AppTec Co., Ltd., Tianjin 300457, China., Zhang R; Department of Chemistry, WuXi AppTec Co., Ltd., Tianjin 300457, China., Osipov M; Denali Therapeutics Inc., South San Francisco, California 94080, United States.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2024 Apr 11; Vol. 67 (7), pp. 5758-5782. Date of Electronic Publication: 2024 Mar 21.
Zobrazit plný text záznamu
6
Akademický článek
Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10.
Autor: Wang X; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Negrou E; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Maloney MT; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Bondar VV; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Andrews SV; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Montalban M; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Llapashtica C; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Maciuca R; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Nguyen H; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Solanoy H; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Arguello A; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Przybyla L; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Moerke NJ; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Huntwork-Rodriguez S; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA., Henry AG; Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA. henry@dnli.com.
Publikováno v: Scientific reports [Sci Rep] 2021 Jun 18; Vol. 11 (1), pp. 12900. Date of Electronic Publication: 2021 Jun 18.
Zobrazit plný text záznamu
7
Akademický článek
Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer.
Autor: Wei S; 1] Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [3] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Kozono S; 1] Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [3] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Kats L; 1] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [2] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA. [3] Department of Pathology, BIDMC, Harvard Medical School, Boston, Massachusetts, USA., Nechama M; 1] Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [3] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Li W; Department of Molecular Biosciences, University of Texas, Austin, Texas, USA., Guarnerio J; 1] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [2] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA. [3] Department of Pathology, BIDMC, Harvard Medical School, Boston, Massachusetts, USA., Luo M; 1] Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [3] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., You MH; Division of Gerontology, Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA., Yao Y; 1] Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [3] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Kondo A; 1] Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [3] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Hu H; 1] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [2] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Bozkurt G; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Moerke NJ; Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA., Cao S; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Reschke M; 1] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [2] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA. [3] Department of Pathology, BIDMC, Harvard Medical School, Boston, Massachusetts, USA., Chen CH; 1] Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [3] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Rego EM; Department of Internal Medicine, University of São Paulo, Ribeirão Preto, Brazil., Lo-Coco F; Department of Biomedicine and Prevention, Tor Vergata University and Santa Lucia Foundation, Rome, Italy., Cantley LC; 1] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [2] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA. [3] Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA., Lee TH; Division of Gerontology, Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA., Wu H; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Zhang Y; Department of Molecular Biosciences, University of Texas, Austin, Texas, USA., Pandolfi PP; 1] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [2] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA. [3] Department of Pathology, BIDMC, Harvard Medical School, Boston, Massachusetts, USA., Zhou XZ; 1] Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [3] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Lu KP; 1] Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [3] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
Publikováno v: Nature medicine [Nat Med] 2015 May; Vol. 21 (5), pp. 457-66. Date of Electronic Publication: 2015 Apr 13.
Zobrazit plný text záznamu
8
Akademický článek
Systematic analysis of BRAF(V600E) melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis.
Autor: Fallahi-Sichani M; HMS LINCS Center, Department of Systems Biology, Harvard Medical School, Boston, MA, USA., Moerke NJ; HMS LINCS Center, Department of Systems Biology, Harvard Medical School, Boston, MA, USA., Niepel M; HMS LINCS Center, Department of Systems Biology, Harvard Medical School, Boston, MA, USA., Zhang T; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Sorger PK; HMS LINCS Center, Department of Systems Biology, Harvard Medical School, Boston, MA, USA peter_sorger@hms.harvard.edu.
Publikováno v: Molecular systems biology [Mol Syst Biol] 2015 Mar 26; Vol. 11 (3), pp. 797. Date of Electronic Publication: 2015 Mar 26.
Zobrazit plný text záznamu
9
Akademický článek
Assay Development and High-Throughput Screening for Inhibitors of Kaposi's Sarcoma-Associated Herpesvirus N-Terminal Latency-Associated Nuclear Antigen Binding to Nucleosomes.
Autor: Beauchemin C; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Moerke NJ; Department of Systems Biology, Harvard Medical School, Boston, MA, USA., Faloon P; Broad Institute, Center for the Science of Therapeutics, Therapeutics Platform, Cambridge, USA., Kaye KM; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA kkaye@rics.bwh.harvard.edu.
Publikováno v: Journal of biomolecular screening [J Biomol Screen] 2014 Jul; Vol. 19 (6), pp. 947-58. Date of Electronic Publication: 2014 Feb 11.
Zobrazit plný text záznamu
10
Akademický článek
Development of in-cell Western assays using far-red fluorophores.
Autor: Moerke NJ; Harvard Medical School, ICCB-Longwood Screening Facility, Boston, Massachusetts., Hoffman GR
Publikováno v: Current protocols in chemical biology [Curr Protoc Chem Biol] 2011 Mar 01; Vol. 3 (1), pp. 39-52.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje